https://www.selleckchem.com/products/msab.html
They were less likely to receive an invasive coronary angiography (67.7% vs 81.0%), percutaneous coronary intervention (PCI) (30.2% vs 53.9%) and dual antiplatelet medication (76.3% vs 88.0%). After adjusting for all the baseline differences, patients with COVID-19 ACS had higher in-hospital (adjusted odds ratio (aOR) 3.27; 95% confidence interval (CI) 2.41-4.42) and 30-day mortality (aOR 6.53; 95% CI 5.1-8.36) compared to patients with the non-COVID-19 ACS. COVID-19 infection was present in 4% of patients hospitalized with an ACS in Engla
Like
Comment
Share
